Clinical Trial Update: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Intismeran Autogene (V940) or placebo with pembrolizumab and chemotherapy in metastatic squamous non-small cell lung cancer; recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Intismeran Autogene (V940) (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Squamous Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING